Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taste Properties of Atazanavir and Cobicistat Formulations
NCT02307656Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2014
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atazanavir and cobicistat in human immunodeficiency virus infection (HIV), sponsored by Bristol Myers Squibb. Primary endpoints: Taste properties of ATV & COBI alone & in combination - Aromatic identity, Taste properties of ATV & COBI alone & in combination - Amplitude and 3 more. Started Dec 2014; status: completed.
02
Drugs
atazanavircobicistat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02307656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307656.